ChromaCode’s HDPCR™ SARS-CoV-2 assay has moved on to the Semi-Finals Round of the XPRIZE Rapid Covid Testing Competition, aiming to increase Covid-19 testing capabilities 100-times past our current standard.
R3 Vascular, a medical device company which developed a technology platform for producing bioresorbable vascular scaffolds (BVS) technology to treat peripheral artery disease, has closed a $17.8 million Series A round. An unnamed corporate investor and 415 CAPITAL led the round. HBM-MedFocus LLC and Wexford Capital also participated. Click here to read more.
Current Health has partnered with the Biomedical Advanced Research and Development Authority (BARDA) – part of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services – to support healthcare providers in monitoring COVID-19 patients, detecting deterioration in their health and predicting disease severity. Current Health’s continuous remote monitoring platform will be used to manage and treat COVID-positive patients and develop a digital biomarker-based algorithm that will be able to predict need for hospitalization and ICU-level care. Click here to read more.
Datavant, a health IT company, received $40 million in Series B funding. Transformation Capital led the round with participation by new investors Johnson & Johnson Innovation – JJDC, Inc. and Cigna Ventures. Existing shareholders also took part, including Roivant Sciences and Flex Capital. Datavant’s technology enables a match between a consenting patient’s study data and their real world data. Click here to read more.
Are you a health IT, diagnostics or life science startup focused on precision medicine or enabling precision medicine or personalized medicine? Submit an application to pitch at INVEST Precision Medicine (virtual) December 9-11. Click here to apply.
Picture: akindo, Getty Images
